OXYCONTIN's oppositions filed in EPO
OXYCONTIN Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US10407434 | PURDUE PHARMA LP | Process for preparing oxycodone compositions |
Mar, 2025
(11 months from now) | |
| US10696684 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5508042 | PURDUE PHARMA LP | Controlled release oxycodone compositions |
Apr, 2013
(11 years ago) | |
| US6488963 | PURDUE PHARMA LP | Hot-melt extrudable pharmaceutical formulation |
Jun, 2017
(6 years ago) | |
| US9060976 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(1 year, 8 months ago) | |
| US8337888 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(1 year, 8 months ago) | |
| US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(10 months ago) | |
| US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(10 months ago) | |
| US10675278 | PURDUE PHARMA LP | Crush resistant delayed-release dosage forms |
Nov, 2023
(5 months ago) | |
| US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8114383 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Oct, 2024
(5 months from now) | |
| US7674799 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7776314 | PURDUE PHARMA LP | Abuse-proofed dosage system |
Apr, 2025
(11 months from now) | |
| US8808741 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492392 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US8894988 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9775808 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492393 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US8894987 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Mar, 2030
(5 years from now) | |
Oxycontin is owned by Purdue Pharma Lp.
Oxycontin contains Oxycodone Hydrochloride.
Oxycontin has a total of 32 drug patents out of which 9 drug patents have expired.
Expired drug patents of Oxycontin are:
- US5508042
- US6488963
- US9060976
- US8337888
- US9675610
- US10369109
- US10675278
- US10130591
- US8309060
Oxycontin was authorised for market use on 05 April, 2010.
Oxycontin is available in tablet, extended release;oral dosage forms.
Oxycontin can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate, management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time.
The generics of Oxycontin are possible to be released after 29 March, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using
OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date:
05 April, 2010Treatment:
Management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time; Management of pain severe enough to require daily, around-the-clock, long ...Dosage:
More Information on Dosage
OXYCONTIN family patents
